Global Got Test Market

Got Test Comprehensive Study by Type (Instruments, Consumables, Others), End Use (Hospitals and Clinics, Diagnostic Laboratories, Others) Players and Region - Global Market Outlook to 2030

Got Test Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Got Test
Enzyme aspartate aminotransferase (AST or GOT) is a bilocular (cytoplasmic and mitochondrial) enzyme with its greatest activity in hepatic and cardiac tissue. Any change in these tissues increases the amount of AST in the bloodstream. The enzyme increases moderately after 6 to 8 hours of initiation in Acute Myocardial Infarction, peaks at around 48 hours, and then recovers to baseline between days 4 and 6. Patients with liver illness, especially those with hepatitis with necrosis, have the highest AST values. AST or GOT testing acquires diagnostic relevance when its values are compared to those of other enzymes of similar tissue origin, allowing to the enzymatic profile of organs such as heart and liver.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Got Test market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Alpha Laboratories (United Kingdom), Biobase Group (United States), ELITechGroup SAS (France), Wiener Laboratorios (Argentina), Horiba Medical. (France), Laboratory Corporation of America Holdings (United States), Randox Laboratories Ltd (United Kingdom), Thermo Fisher Scientific Inc. (United States), Abbott Laboratories (United States) and F. Hoffmann-La Roche AG (Switzerland) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Got Test market by Type (Instruments, Consumables and Others) and Region.



On the basis of geography, the market of Got Test has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End Use, the sub-segment i.e. Hospitals and Clinics will boost the Got Test market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Rising Geriatric Population

Market Growth Drivers:
Prevalence of Hepatitis Cases and High Investment in Healthcare R&D

Challenges:
Fierce Competitive pressure and High Cost Expenses

Restraints:
Lack of Skilled Professionals

Opportunities:
Growing Healthcare Infrastructure Across Emerging Regions

Market Leaders and their expansionary development strategies
In 2020, Quest Diagnostics announced a pilot program for drone delivery of COVID-19 at-home self-collection kits to single-family homes in the Cheektowaga area.
In 2020, LabCorp launched a combined test for RSV, flu, and COVID-19. The company has applied for U.S. FDA approval to use this test with its Pixel by LabCorp at-home test collection kit.


Key Target Audience
Got Test Kit Manufactures, New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Instruments
  • Consumables
  • Others
By End Use
  • Hospitals and Clinics
  • Diagnostic Laboratories
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Prevalence of Hepatitis Cases
      • 3.2.2. High Investment in Healthcare R&D
    • 3.3. Market Challenges
      • 3.3.1. Fierce Competitive pressure
      • 3.3.2. High Cost Expenses
    • 3.4. Market Trends
      • 3.4.1. Rising Geriatric Population
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Got Test, by Type, End Use and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Got Test (Value)
      • 5.2.1. Global Got Test by: Type (Value)
        • 5.2.1.1. Instruments
        • 5.2.1.2. Consumables
        • 5.2.1.3. Others
      • 5.2.2. Global Got Test by: End Use (Value)
        • 5.2.2.1. Hospitals and Clinics
        • 5.2.2.2. Diagnostic Laboratories
        • 5.2.2.3. Others
      • 5.2.3. Global Got Test Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Got Test: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Alpha Laboratories (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Biobase Group (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. ELITechGroup SAS (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Wiener Laboratorios (Argentina)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Horiba Medical. (France)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Laboratory Corporation of America Holdings (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Randox Laboratories Ltd (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Thermo Fisher Scientific Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Abbott Laboratories (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. F. Hoffmann-La Roche AG (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Got Test Sale, by Type, End Use and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Got Test (Value)
      • 7.2.1. Global Got Test by: Type (Value)
        • 7.2.1.1. Instruments
        • 7.2.1.2. Consumables
        • 7.2.1.3. Others
      • 7.2.2. Global Got Test by: End Use (Value)
        • 7.2.2.1. Hospitals and Clinics
        • 7.2.2.2. Diagnostic Laboratories
        • 7.2.2.3. Others
      • 7.2.3. Global Got Test Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Got Test: by Type(USD Million)
  • Table 2. Got Test Instruments , by Region USD Million (2018-2023)
  • Table 3. Got Test Consumables , by Region USD Million (2018-2023)
  • Table 4. Got Test Others , by Region USD Million (2018-2023)
  • Table 5. Got Test: by End Use(USD Million)
  • Table 6. Got Test Hospitals and Clinics , by Region USD Million (2018-2023)
  • Table 7. Got Test Diagnostic Laboratories , by Region USD Million (2018-2023)
  • Table 8. Got Test Others , by Region USD Million (2018-2023)
  • Table 9. South America Got Test, by Country USD Million (2018-2023)
  • Table 10. South America Got Test, by Type USD Million (2018-2023)
  • Table 11. South America Got Test, by End Use USD Million (2018-2023)
  • Table 12. Brazil Got Test, by Type USD Million (2018-2023)
  • Table 13. Brazil Got Test, by End Use USD Million (2018-2023)
  • Table 14. Argentina Got Test, by Type USD Million (2018-2023)
  • Table 15. Argentina Got Test, by End Use USD Million (2018-2023)
  • Table 16. Rest of South America Got Test, by Type USD Million (2018-2023)
  • Table 17. Rest of South America Got Test, by End Use USD Million (2018-2023)
  • Table 18. Asia Pacific Got Test, by Country USD Million (2018-2023)
  • Table 19. Asia Pacific Got Test, by Type USD Million (2018-2023)
  • Table 20. Asia Pacific Got Test, by End Use USD Million (2018-2023)
  • Table 21. China Got Test, by Type USD Million (2018-2023)
  • Table 22. China Got Test, by End Use USD Million (2018-2023)
  • Table 23. Japan Got Test, by Type USD Million (2018-2023)
  • Table 24. Japan Got Test, by End Use USD Million (2018-2023)
  • Table 25. India Got Test, by Type USD Million (2018-2023)
  • Table 26. India Got Test, by End Use USD Million (2018-2023)
  • Table 27. South Korea Got Test, by Type USD Million (2018-2023)
  • Table 28. South Korea Got Test, by End Use USD Million (2018-2023)
  • Table 29. Taiwan Got Test, by Type USD Million (2018-2023)
  • Table 30. Taiwan Got Test, by End Use USD Million (2018-2023)
  • Table 31. Australia Got Test, by Type USD Million (2018-2023)
  • Table 32. Australia Got Test, by End Use USD Million (2018-2023)
  • Table 33. Rest of Asia-Pacific Got Test, by Type USD Million (2018-2023)
  • Table 34. Rest of Asia-Pacific Got Test, by End Use USD Million (2018-2023)
  • Table 35. Europe Got Test, by Country USD Million (2018-2023)
  • Table 36. Europe Got Test, by Type USD Million (2018-2023)
  • Table 37. Europe Got Test, by End Use USD Million (2018-2023)
  • Table 38. Germany Got Test, by Type USD Million (2018-2023)
  • Table 39. Germany Got Test, by End Use USD Million (2018-2023)
  • Table 40. France Got Test, by Type USD Million (2018-2023)
  • Table 41. France Got Test, by End Use USD Million (2018-2023)
  • Table 42. Italy Got Test, by Type USD Million (2018-2023)
  • Table 43. Italy Got Test, by End Use USD Million (2018-2023)
  • Table 44. United Kingdom Got Test, by Type USD Million (2018-2023)
  • Table 45. United Kingdom Got Test, by End Use USD Million (2018-2023)
  • Table 46. Netherlands Got Test, by Type USD Million (2018-2023)
  • Table 47. Netherlands Got Test, by End Use USD Million (2018-2023)
  • Table 48. Rest of Europe Got Test, by Type USD Million (2018-2023)
  • Table 49. Rest of Europe Got Test, by End Use USD Million (2018-2023)
  • Table 50. MEA Got Test, by Country USD Million (2018-2023)
  • Table 51. MEA Got Test, by Type USD Million (2018-2023)
  • Table 52. MEA Got Test, by End Use USD Million (2018-2023)
  • Table 53. Middle East Got Test, by Type USD Million (2018-2023)
  • Table 54. Middle East Got Test, by End Use USD Million (2018-2023)
  • Table 55. Africa Got Test, by Type USD Million (2018-2023)
  • Table 56. Africa Got Test, by End Use USD Million (2018-2023)
  • Table 57. North America Got Test, by Country USD Million (2018-2023)
  • Table 58. North America Got Test, by Type USD Million (2018-2023)
  • Table 59. North America Got Test, by End Use USD Million (2018-2023)
  • Table 60. United States Got Test, by Type USD Million (2018-2023)
  • Table 61. United States Got Test, by End Use USD Million (2018-2023)
  • Table 62. Canada Got Test, by Type USD Million (2018-2023)
  • Table 63. Canada Got Test, by End Use USD Million (2018-2023)
  • Table 64. Mexico Got Test, by Type USD Million (2018-2023)
  • Table 65. Mexico Got Test, by End Use USD Million (2018-2023)
  • Table 66. Company Basic Information, Sales Area and Its Competitors
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Got Test: by Type(USD Million)
  • Table 77. Got Test Instruments , by Region USD Million (2025-2030)
  • Table 78. Got Test Consumables , by Region USD Million (2025-2030)
  • Table 79. Got Test Others , by Region USD Million (2025-2030)
  • Table 80. Got Test: by End Use(USD Million)
  • Table 81. Got Test Hospitals and Clinics , by Region USD Million (2025-2030)
  • Table 82. Got Test Diagnostic Laboratories , by Region USD Million (2025-2030)
  • Table 83. Got Test Others , by Region USD Million (2025-2030)
  • Table 84. South America Got Test, by Country USD Million (2025-2030)
  • Table 85. South America Got Test, by Type USD Million (2025-2030)
  • Table 86. South America Got Test, by End Use USD Million (2025-2030)
  • Table 87. Brazil Got Test, by Type USD Million (2025-2030)
  • Table 88. Brazil Got Test, by End Use USD Million (2025-2030)
  • Table 89. Argentina Got Test, by Type USD Million (2025-2030)
  • Table 90. Argentina Got Test, by End Use USD Million (2025-2030)
  • Table 91. Rest of South America Got Test, by Type USD Million (2025-2030)
  • Table 92. Rest of South America Got Test, by End Use USD Million (2025-2030)
  • Table 93. Asia Pacific Got Test, by Country USD Million (2025-2030)
  • Table 94. Asia Pacific Got Test, by Type USD Million (2025-2030)
  • Table 95. Asia Pacific Got Test, by End Use USD Million (2025-2030)
  • Table 96. China Got Test, by Type USD Million (2025-2030)
  • Table 97. China Got Test, by End Use USD Million (2025-2030)
  • Table 98. Japan Got Test, by Type USD Million (2025-2030)
  • Table 99. Japan Got Test, by End Use USD Million (2025-2030)
  • Table 100. India Got Test, by Type USD Million (2025-2030)
  • Table 101. India Got Test, by End Use USD Million (2025-2030)
  • Table 102. South Korea Got Test, by Type USD Million (2025-2030)
  • Table 103. South Korea Got Test, by End Use USD Million (2025-2030)
  • Table 104. Taiwan Got Test, by Type USD Million (2025-2030)
  • Table 105. Taiwan Got Test, by End Use USD Million (2025-2030)
  • Table 106. Australia Got Test, by Type USD Million (2025-2030)
  • Table 107. Australia Got Test, by End Use USD Million (2025-2030)
  • Table 108. Rest of Asia-Pacific Got Test, by Type USD Million (2025-2030)
  • Table 109. Rest of Asia-Pacific Got Test, by End Use USD Million (2025-2030)
  • Table 110. Europe Got Test, by Country USD Million (2025-2030)
  • Table 111. Europe Got Test, by Type USD Million (2025-2030)
  • Table 112. Europe Got Test, by End Use USD Million (2025-2030)
  • Table 113. Germany Got Test, by Type USD Million (2025-2030)
  • Table 114. Germany Got Test, by End Use USD Million (2025-2030)
  • Table 115. France Got Test, by Type USD Million (2025-2030)
  • Table 116. France Got Test, by End Use USD Million (2025-2030)
  • Table 117. Italy Got Test, by Type USD Million (2025-2030)
  • Table 118. Italy Got Test, by End Use USD Million (2025-2030)
  • Table 119. United Kingdom Got Test, by Type USD Million (2025-2030)
  • Table 120. United Kingdom Got Test, by End Use USD Million (2025-2030)
  • Table 121. Netherlands Got Test, by Type USD Million (2025-2030)
  • Table 122. Netherlands Got Test, by End Use USD Million (2025-2030)
  • Table 123. Rest of Europe Got Test, by Type USD Million (2025-2030)
  • Table 124. Rest of Europe Got Test, by End Use USD Million (2025-2030)
  • Table 125. MEA Got Test, by Country USD Million (2025-2030)
  • Table 126. MEA Got Test, by Type USD Million (2025-2030)
  • Table 127. MEA Got Test, by End Use USD Million (2025-2030)
  • Table 128. Middle East Got Test, by Type USD Million (2025-2030)
  • Table 129. Middle East Got Test, by End Use USD Million (2025-2030)
  • Table 130. Africa Got Test, by Type USD Million (2025-2030)
  • Table 131. Africa Got Test, by End Use USD Million (2025-2030)
  • Table 132. North America Got Test, by Country USD Million (2025-2030)
  • Table 133. North America Got Test, by Type USD Million (2025-2030)
  • Table 134. North America Got Test, by End Use USD Million (2025-2030)
  • Table 135. United States Got Test, by Type USD Million (2025-2030)
  • Table 136. United States Got Test, by End Use USD Million (2025-2030)
  • Table 137. Canada Got Test, by Type USD Million (2025-2030)
  • Table 138. Canada Got Test, by End Use USD Million (2025-2030)
  • Table 139. Mexico Got Test, by Type USD Million (2025-2030)
  • Table 140. Mexico Got Test, by End Use USD Million (2025-2030)
  • Table 141. Research Programs/Design for This Report
  • Table 142. Key Data Information from Secondary Sources
  • Table 143. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Got Test: by Type USD Million (2018-2023)
  • Figure 5. Global Got Test: by End Use USD Million (2018-2023)
  • Figure 6. South America Got Test Share (%), by Country
  • Figure 7. Asia Pacific Got Test Share (%), by Country
  • Figure 8. Europe Got Test Share (%), by Country
  • Figure 9. MEA Got Test Share (%), by Country
  • Figure 10. North America Got Test Share (%), by Country
  • Figure 11. Global Got Test share by Players 2023 (%)
  • Figure 12. Global Got Test share by Players (Top 3) 2023(%)
  • Figure 13. Global Got Test share by Players (Top 5) 2023(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Alpha Laboratories (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 16. Alpha Laboratories (United Kingdom) Revenue: by Geography 2023
  • Figure 17. Biobase Group (United States) Revenue, Net Income and Gross profit
  • Figure 18. Biobase Group (United States) Revenue: by Geography 2023
  • Figure 19. ELITechGroup SAS (France) Revenue, Net Income and Gross profit
  • Figure 20. ELITechGroup SAS (France) Revenue: by Geography 2023
  • Figure 21. Wiener Laboratorios (Argentina) Revenue, Net Income and Gross profit
  • Figure 22. Wiener Laboratorios (Argentina) Revenue: by Geography 2023
  • Figure 23. Horiba Medical. (France) Revenue, Net Income and Gross profit
  • Figure 24. Horiba Medical. (France) Revenue: by Geography 2023
  • Figure 25. Laboratory Corporation of America Holdings (United States) Revenue, Net Income and Gross profit
  • Figure 26. Laboratory Corporation of America Holdings (United States) Revenue: by Geography 2023
  • Figure 27. Randox Laboratories Ltd (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 28. Randox Laboratories Ltd (United Kingdom) Revenue: by Geography 2023
  • Figure 29. Thermo Fisher Scientific Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Thermo Fisher Scientific Inc. (United States) Revenue: by Geography 2023
  • Figure 31. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 32. Abbott Laboratories (United States) Revenue: by Geography 2023
  • Figure 33. F. Hoffmann-La Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 34. F. Hoffmann-La Roche AG (Switzerland) Revenue: by Geography 2023
  • Figure 35. Global Got Test: by Type USD Million (2025-2030)
  • Figure 36. Global Got Test: by End Use USD Million (2025-2030)
  • Figure 37. South America Got Test Share (%), by Country
  • Figure 38. Asia Pacific Got Test Share (%), by Country
  • Figure 39. Europe Got Test Share (%), by Country
  • Figure 40. MEA Got Test Share (%), by Country
  • Figure 41. North America Got Test Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Alpha Laboratories (United Kingdom)
  • Biobase Group (United States)
  • ELITechGroup SAS (France)
  • Wiener Laboratorios (Argentina)
  • Horiba Medical. (France)
  • Laboratory Corporation of America Holdings (United States)
  • Randox Laboratories Ltd (United Kingdom)
  • Thermo Fisher Scientific Inc. (United States)
  • Abbott Laboratories (United States)
  • F. Hoffmann-La Roche AG (Switzerland)
Select User Access Type

Key Highlights of Report


Feb 2024 166 Pages 85 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Got Test Market Quantitative research analysis
Global Got Test Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Alpha Laboratories (United Kingdom), Biobase Group (United States), ELITechGroup SAS (France), Wiener Laboratorios (Argentina), Horiba Medical. (France), Laboratory Corporation of America Holdings (United States), Randox Laboratories Ltd (United Kingdom), Thermo Fisher Scientific Inc. (United States), Abbott Laboratories (United States) and F. Hoffmann-La Roche AG (Switzerland) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Rising Geriatric Population" is seen as one of major influencing trends for Got Test Market during projected period 2023-2030.
The Got Test market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Got Test Market Report?

Have a Query? Click Here

Other Related Reports

Meat Species Identification Kits Comprehensive Study by Type (PCR and Real-Time PCR, Enzyme-Linked Immunosorbent Assay (ELISA)), End Use (Restaurant & Hotels, Food Agencies, Others), Meat (Raw Meat, ...
$ 3500
Radiopharmaceutical Theranostics Comprehensive Study by Type (Technetium-99, Gallium-68, Iodine-131, Iodine-123, Fluorine-18, Lutetium (Lu) 177, Copper (Cu) 67, Others), Application (Oncology, Cardio...
$ 3650
Health Status Monitoring Comprehensive Study by Type (Blood Glucose Monitoring Systems, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Temperature Monitoring Devices, Others), Category (...
$ 3450
Artificial Intelligence In Remote Patient Monitoring Comprehensive Study by Type (Wireless, Portable, Real-time, Continuous), Application (Wearable heart monitors, Bluetooth-enabled scales, Glucose m...
$ 3650
Nucleic Acid Electrophoresis Comprehensive Study by Application (Research, Diagnostics), End Users (Research Institutes, Hospitals, Diagnostics Centre), Instrument (Horizontal Gel Electrophoresis Sys...
$ 3450
Augmented Intelligence in Healthcare Comprehensive Study by Application (Care Coordination Command Center, Mental Health Tracking, Population Health Management, Research & Drug Discovery, Precision M...
$ 3750